MetLife Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

MetLife Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$208K	Buy	30,048 +5,638	+23%	+$43.5K	﹤0.01%	2208
2025 Q4	$215K	Sell	24,410 -7,899	-24%	-$43.5K	﹤0.01%	2238
2025 Q3	$161K	Sell	32,309 -551	-2%	-$2.55K	﹤0.01%	2428
2025 Q2	$155K	Buy	32,860 +44	+0.1%	+$192	﹤0.01%	2314
2025 Q1	$151K	Buy	32,816 +5,210	+19%	+$24.3K	﹤0.01%	2337
2024 Q4	$132K	Sell	27,606 -5,482	-17%	-$26.3K	﹤0.01%	2501
2024 Q3	$155K	Hold	33,088	–	–	﹤0.01%	2419
2024 Q2	$187K	Buy	33,088 +3,324	+11%	+$17.2K	﹤0.01%	2292
2024 Q1	$122K	Sell	29,764 -837	-3%	-$3.35K	﹤0.01%	2446
2023 Q4	$129K	Hold	30,601	–	–	﹤0.01%	2479
2023 Q3	$132K	Hold	30,601	–	–	﹤0.01%	2439
2023 Q2	$202K	Hold	30,601	–	–	﹤0.01%	2272
2023 Q1	$208K	Hold	30,601	–	–	﹤0.01%	2197
2022 Q4	$226K	Hold	30,601	–	–	﹤0.01%	2178
2022 Q3	$302K	Hold	30,601	–	–	﹤0.01%	2018
2022 Q2	$334K	Hold	30,601	–	–	﹤0.01%	1950
2022 Q1	$346K	Buy	30,601 +10,989	+56%	+$144K	﹤0.01%	2006
2021 Q4	$308K	Buy	19,612 +3,281	+20%	+$57.2K	﹤0.01%	1798
2021 Q3	$280K	Sell	16,331 -5,053	-24%	-$88.5K	﹤0.01%	1865
2021 Q2	$460K	Hold	21,384	–	–	﹤0.01%	1618
2021 Q1	$321K	Sell	21,384 -2,952	-12%	-$47.8K	﹤0.01%	1775
2020 Q4	$320K	Hold	24,336	–	–	﹤0.01%	1728
2020 Q3	$235K	Hold	24,336	–	–	﹤0.01%	1766
2020 Q2	$278K	Hold	24,336	–	–	﹤0.01%	1701
2020 Q1	$252K	Hold	24,336	–	–	﹤0.01%	1572
2019 Q4	$399K	Hold	24,336	–	–	﹤0.01%	1581
2019 Q3	$323K	Hold	24,336	–	–	﹤0.01%	1659
2019 Q2	$343K	Hold	24,336	–	–	﹤0.01%	1713
2019 Q1	$448K	Hold	24,336	–	–	﹤0.01%	1518
2018 Q4	$636K	Hold	24,336	–	–	0.01%	1219
2018 Q3	$559K	Hold	24,336	–	–	0.01%	1466
2018 Q2	$464K	Buy	24,336 +4,063	+20%	+$67.9K	0.01%	1446
2018 Q1	$342K	Hold	20,273	–	–	﹤0.01%	1609
2017 Q4	$308K	Buy	+20,273	New	+$301K	﹤0.01%	1694

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's VNDA Position: Q1 2026 in Review

MetLife Investment Management increased its Vanda Pharmaceuticals (VNDA) stake by 23% in Q1 2026, buying an estimated $43.5K and bringing the position to 30,048 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

MetLife Investment Management first reported a position in VNDA in Q4 2017 and has held it in 34 quarters since. The position peaked at $636K in Q4 2018. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

MetLife Investment Management held 30,048 shares of Vanda Pharmaceuticals worth $208K as of Q1 2026.
MetLife Investment Management bought 5,638 Vanda Pharmaceuticals shares in Q1 2026, an estimated $43.5K.
Vanda Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2208 holding.
MetLife Investment Management first reported a position in Vanda Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
MetLife Investment Management's Vanda Pharmaceuticals position peaked at $636K in Q4 2018.
170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.